Milestone Pharma raises $17 mln

By Luisa Beltran — 8 months ago

Milestone Pharmaceuticals Inc. said Monday that it closed a $17 million series B financing led by Domain Associates. All of Milestone’s existing investors including Fonds de solidarité FTQ , Pappas Ventures, BDC Capital, GO Capital and iNovia Capital participated in the round. Montreal-based Milestone Pharma is a clinical stage cardiovascular company.

Continue

Milestone Pharmaceuticals picks up $17 mln

By Iris Dorbian — 8 months ago

Canada-based Milestone Pharmaceuticals, a drug developer focused on cardiovascular diseases, has raised $17 million in Series B funding. Domain Associates led the round with participation from other investors that included Fonds de solidarité FTQ, Pappas Ventures, BDC Capital, GO Capital and iNovia Capital. In conjunction with the funding, Domain’s Debra Liebert has been added to Milestone’s board of directors.

Continue

CoLucid Pharmaceuticals nabs $37.1 mln

By Iris Dorbian — 1 year ago

Durham, North Carolina-based CoLucid Pharmaceuticals, which develops oral lasmiditan that treats migraine headaches, has raised $37.1 million in Series C funding. TVM Capital Life Science led the round with participation from other investors Novo Ventures, Auriga Partners, Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures. Also, Dr. Luc Marengere of TVM Capital Life Science and Dr. Martin Edwards of Novo Ventures have been added to CoLucid’s board of directors.

Continue

Rotation Medical snags $27.2 mln Series B

By Iris Dorbian — 2 years ago

Rotation Medical, a medical device firm focused on rotator cuff disease, has closed $27.2 million in Series B funding. Life Sciences Partners and New Enterprise Associates led the round with participation from investors that included Pappas Ventures. In conjunction with the funding, Dr. Azzam of LSP and Scott Weiner of Pappas Ventures have been added to Rotation Medical’s board of directors.

Continue

Shire acquires VC-backed Lumena Pharmaceuticals

By Iris Dorbian — 2 years ago

Shire has acquired Lumena Pharmaceuticals. No financial terms were disclosed. Citi provided financial advice to Lumena. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders. Its backers include New Enterprise Associates, Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners.

Continue

VC-backed Syndax Pharmaceuticals files for IPO

By Iris Dorbian — 2 years ago

Syndax Pharmaceuticals has filed for an IPO. The number of shares that will be offered as well as the stock’s pricing terms have yet to be set. Deutsche Bank Securities and Jefferies are serving as lead underwriters. Headquartered in Waltham, Mass., Syndax is a Syndax Pharmaceuticals is a developer of epigenetic therapies for treatment-resistant cancers. Its backers include Domain Associates, MPM Capital, Forward Ventures, Pappas Ventures and Avalon Ventures.

Continue

Lumena attracts $45 mln in Series B funds

By Iris Dorbian — 2 years ago

Lumena Pharmaceuticals said Tuesday that it has closed $45 million in Series B financing. New Enterprise Associates led the round with participation from Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders.

Continue

Tesaro Closes $101M

5 years ago

Biopharmaceutical company Tesaro Inc. has closed a whopping $101 million Series B round led by Kleiner Perkins Caufield & Byers. Existing shareholder New Enterprise Associates also participated, as did new investors InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Management and Leerink Swann. Tesaro is focused on oncology-related products, including a drug to prevent chemotherapy-induced nausea. The company sealed a $20 million Series A round in 2010.

Continue

Ultragenyx Seals $45M Series A

5 years ago

One-year-old start-up Ultragenyx Pharmaceutical Inc. has closed on a whopping $45 million Series A round co-led by TPG Biotech and Fidelity Biosciences. Other investors include HealthCap and Pappas Ventures. The money will help Novato, Calif.-based Ultragenyx continue development of its rare disease therapeutics. As a result of the round, Eran Nadav of TPG Biotech; Ben Auspitz of Fidelity Biosciences; and Mårten Steen of HealthCap will join the company’s board.

Continue

Milestone Pharma Inks $13M

5 years ago

Milestone Pharmaceuticals Inc., a Montreal-based cardiovascular drug development company, has raised $13 million in fresh capital. Pappas Ventures, the Business Development Bank of Canada and GO Capital co-led the round. Fonds de solidarité FTQ, iNovia Healthcare Ventures and Fonds Bio-Innovation also participated. The money will be used for continued development. As a result of the round, Eric Linsley, managing partner of Pappas Ventures; Scott Weiner, senior principal at Pappas Ventures; and Dominic Jaikaran, principal at BDC Health Venture Fund, will join Milestone’s board.

Continue

Syndax Pharma Takes New Board Member

By Jonathan Marino — 5 years ago

Syndax Pharmaceuticals, the Massachusetts-based oncology company, took on Arlene Morris to its board of directors. Morris was most recently the CEO and board member of Affymax Inc., the biopharma company spun from GlaxoSmithKline. Among Syndax’s backers are Domain Associates, MPM Capital, Avalon, Pappas and Forward Ventures.

Continue

CardioDx Seals $60M in Equity Financing

5 years ago

CardioDx, a company developing cardiovascular genomic diagnostics, has raised $60 million in new equity funding. New investors Longitude Capital, J.P. Morgan, Acadia Woods Partners, Artiman Ventures, and Bright Capital, the venture arm of RU-COM, participated in the round, which also included the company’s previous investors. The company has raised money previously from Kleiner, Perkins, Caufield & Byers, Mohr Davidow Ventures, TPG Biotech, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group and GE Capital. Funding will be used to expand reimbursement coverage in the United States for the company’s blood-based gene expression test for obstructive coronary artery disease, as well as to continue development of future products. The company, based in Palo Alto, Calif., closed a $45 million round in May 2010.

Continue

Gimv, Others Exit Investment in Plexxikon

5 years ago

Daiichi Sankyo has agreed to buy Plexxikon for $805 million, providing an exit for venture investors including Belgian firm GIMV. Future milestone payments could total an additional $130 million, the company said. Plexxikon develops novel small molecule pharmaceuticals to treat human disease. Gimv first invested in Plexxikon during a series B financing in 2002. The company is also backed by Alta Partners, ATV, Walden International, Pappas Ventures and CW Ventures.

Continue

Medical Device Maker TYRX Inks $20 Million

5 years ago

New Jersey-based medical device company TYRX has raised $20 million in a round led by new investor HLM Venture Partners. The company’s previous investors Clarus Ventures and North Carolina-based Pappas Ventures also contributed to the round. The financing also included $4 million in debt financing from Comerica Bank. HLM Venture Partners’ Edward Cahill joins the TYRX board as a result of the financing. Clarus Ventures has offices in Cambridge, Mass., and in San Francisco. HLM Venture Partners is based in Boston and San Francisco.

Continue

Michael Grey Joins Pappas Ventures

By PEHub Administrator — 6 years ago

Michael Grey has been named a venture partners with Pappas Ventures. Grey has served as a member of the firm’s scientific advisory board for the past six years, and has served as CEO of Auspex Pharmaceuticals, SGX Pharmaceuticals (acquired by Eli Lilly) and Trega Biosciences (acquired by Lion Bioscience).

Continue

Afferent Pharma Raises $23 Million

By PEHub Administrator — 6 years ago

Afferent Pharmaceuticals, a Palo Alto, Calif.-based developer of drugs for chronic pain, has raised $23 million in Series A funding. Third Rock Ventures and Pappas Ventures co-led the round, and were joined by Domain Associates and New Leaf Venture Partners. In related news, Afferent has licensed a chronic pain program from Roche.

Continue